myTRIAList’s Post

Have you watched any of our trial-overview videos, such as the STELLAR-305 study, designed to engage patients and empower them to start conversations with their care providers? Learn more here: https://buff.ly/4bKB08r #carcinoma #research #clinicaltrials #pharma #biotech #oncology CancerCare

Need support in colon clinical trial patient recruitment? Watch this video to learn more about our trial overview videos, including the AZUR-2 study, and how these plain-language videos are designed to expand enrollment in cancer clinical trials here: https://buff.ly/48zuUFY #coloncancer #oncology #pharma #biotech #science

In search of advanced or metastatic non-clear cell renal cell carcinoma clinical trial options for your patients living with cancer? Try searching for trials via CancerCare's myTRIAList trial finder and explore clinical trial options that might be right for you, such as the STELLAR-304 study. https://buff.ly/3thMHTv #clinicaltrials #pharmaceutical #biotechnology #science #research #solutions

Have you tried searching for rectal cancer clinical trials via CancerCare's myTRIAList clinical trial finder yet? Watch trial overview videos, including the AZUR-1 study overview video, that are designed to explain study details in plain language. https://buff.ly/4aNkFA2 #rectalcancer #cancerresearch #pharmaceuticalindustry #biotech

WATCH: Experts discuss several recent data updates in polycythemia vera and myelofibrosis in the context of the treatment landscape and its impact on clinical practice. #oncology https://lnkd.in/e3eHM6K7

With major advances in the understanding of cancer, the cancer treatment landscape has evolved, resulting in significant changes in therapy and in turn the primary endpoints elected for cancer clinical trials. Experts emphasize the need for transparency when changing primary endpoints in oncology clinical trials.

Rethinking Clinical Trials in Oncology: Embracing Pragmatic Approaches Traditional randomized controlled trials (RCTs) in oncology often come with heavy monitoring, numerous assessments, and frequent follow-up visits. While essential for rigorous data, these demands can be overwhelming for participants, investigators, and sponsors alike. FDA believes that it's time to consider pragmatic clinical trials that mirror routine clinical practice more closely. These trials can streamline processes and focus on demonstrating efficacy with clear, straightforward endpoints like overall survival. For example, a critical question we should be asking is, "What is the median overall survival for patients with [specific type of cancer] treated with drug X versus drug Y?" By adopting pragmatic approaches, we can reduce the burden on all stakeholders while still obtaining valuable, real-world data. How is this possible? Let FDA know your two cents! It's its one-of-a-kind approach, #FDA wants you to share your ideas! This initiative allows the #innovators and key stakeholders in the field, to voice their opinion where it's heard the clearest! #Oncology #ClinicalTrials #HealthcareInnovation #PatientCentric #MedicalResearch Link to my two cents 👛: https://lnkd.in/ecgtkNJJ

Clinical Trials Save Lives! Read about the potential advantages and disadvantages of participating in clinical trials. https://lnkd.in/geTZAJNq #ClinicalResearch #GlobalCRO #CRO #ClinicalTrials #Biotech #ClinicalProjectManagement #GlobalContractResearchOrganization #PatientRecruitmentServices #PharmaceuticalResearch #ContractResearchOrganization #ClinicalTrialManagement #DrugDevelopment #DecentralizedClinicalTrials #APAC #MiddleEast #Africa #Oncology #Thoracic #HepatocellularCarcinoma #MedTech #PopulationScience #HealthEquity #ThoracicClinicalTrials #HealthLiteracy #InclusiveClinicalResearch #GlobalCommunity

Diversity in clinical trials - have you given any thoughts about your diversity plans? How exactly can you execute these plans? More importantly... where to even start? Fortrea offers a comprehensive and integrated "5-part process" solution for establishing, monitoring and reporting on Diversity Plan metrics in a clinical trials. Curious? Drop me a message! Or take a look at Joshua Richter's article - discusses the lack of diversity in clinical trials and how community oncologists can help overcome these disparities. #DiversityPlan #ClinicalTrials #oncology #diversity #Phase3

Congrats to our clinical data manager Sara Anderson (Weigel) who spoke at the 2024 Zelta User Conference hosted by Merative in Boston earlier this month. Sara shared her perspective on how SPR Therapeutics leverages Zelta for post-market, retrospective real-world data collection.    Zelta is a large part of our clinical study process. We use their clinical data management platform to build and house the databases for our clinical trials. When our study sites enter subject data into the system, it provides our clinical and R&D teams with the ability to monitor, compile and analyze the data. The data is then used to develop abstracts, journal articles and symposium presentations. It is a tool that allows us to be true partners with all of our clinical study sites and offer real-world perspectives in data to educate others about peripheral nerve stimulation.   #PNS #SprintPNS #neuromodulation #clinicaltrials #clinicaldata #clinicalstudies #professionaleducation #leadersinmeddevice #meddeviceleaders